{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:52:52Z","timestamp":1785462772168,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["1215-200074"],"award-info":[{"award-number":["1215-200074"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Women at increased familial breast cancer risk have been offered screening starting at an earlier age and increased frequency than national Screening Programmes for over 30\u00a0years. There are limited data on longer-term largescale implementation of this approach on cancer diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women at our institution at\u2009\u2265\u200917% lifetime breast cancer risk have been offered enhanced screening with annual mammography starting at age 35 or 5-years younger than youngest affected relative, with upper age limit 50 for moderate and 60 for high-risk. Breast cancer pathology, stage and receptor status were assessed as well as survival from cancer diagnosis by Kaplan\u2013Meier analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall 14,311 women were seen and assessed for breast cancer risk, with 649 breast cancers occurring in 129,119\u00a0years follow up (post-prevalent annual incidence\u2009=\u20094.55\/1000). Of 323\/394 invasive breast cancers occurring whilst on enhanced screening, most were lymph-node negative (72.9%), T1 (\u2264\u200920\u00a0mm, 73.2%) and stage-1 (61.4%), 126\/394 stage2\u20134 (32%). 10-year breast cancer specific survival was 91.3% (95% CI 87.4\u201394.0) better than the 75.9% (95% CI 74.9\u201377.0) published for England in 2013\u20132017. As expected, survival was significantly better for women with screen detected cancers (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Ten-year survival was particularly good for those diagnosed\u2009\u2264\u200940 at 93.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200975; 95% CI 84.2\u201397.6). Women with lobular breast cancers had worse 10-year survival at 85.9% (95% CI 66.7\u201394.5). Breast cancer specific survival was good for 119\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      carriers with 20-year survival in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      :91.2% (95% CI 77.8\u201396.6) and 83.8% (62.6\u201393.5) for\n                      <jats:italic>BRCA2.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeted breast screening in women aged 30\u201360\u00a0years at increased familial risk is associated with good long-term survival that is substantially better than expected from population data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-021-06333-1","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T12:04:35Z","timestamp":1627301075000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women"],"prefix":"10.1007","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D. Gareth","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashu","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke M.","family":"van Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma R.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yit","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine F.","family":"Harkness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"6333_CR1","unstructured":"https:\/\/www.cancerresearchuk.org\/about-cancer\/breast-cancer\/risks-causes\/risk-factors. Accessed 19 April 2020"},{"issue":"12","key":"6333_CR2","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.3390\/cancers12123697","volume":"12","author":"A Howell","year":"2020","unstructured":"Howell A, Gandhi A, Howell S, Wilson M, Maxwell A, Astley S, Harvie M, Pegington M, Barr L, Baildam A, Harkness E, Hopwood P, Wisely J, Wilding A, Greenhalgh R, Affen J, Maurice A, Cole S, Wiseman J, Lalloo F, French DP, Evans DG (2020) Long-term evaluation of women referred to a breast cancer family history clinic (Manchester UK 1987\u20132020). Cancers (Basel) 12(12):3697. https:\/\/doi.org\/10.3390\/cancers12123697","journal-title":"Cancers (Basel)"},{"issue":"6922","key":"6333_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/bmj.308.6922.183","volume":"308","author":"DG Evans","year":"1994","unstructured":"Evans DG, Fentiman IS, McPherson K, Asbury D, Ponder BA, Howell A (1994) Familial breast cancer. BMJ 308(6922):183\u2013187","journal-title":"BMJ"},{"key":"6333_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/jmg.37.3.203","volume":"37","author":"DM Eccles","year":"2000","unstructured":"Eccles DM, Evans DGR, Mackay J (2000) Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet 37:203\u2013209","journal-title":"J Med Genet"},{"key":"6333_CR5","unstructured":"McIntosh A, Shaw C, Evans G et al (2004) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer, London: National Collaborating Centre for Primary Care\/University of Sheffield. NICE guideline CG164. https:\/\/www.nice.org.uk\/Guidance\/CG164. Accessed 2 Feb 2021"},{"issue":"3","key":"6333_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","volume":"73","author":"EB Claus","year":"1994","unstructured":"Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73(3):643\u2013651","journal-title":"Cancer"},{"issue":"7","key":"6333_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111\u20131130. https:\/\/doi.org\/10.1002\/sim.1668","journal-title":"Stat Med"},{"issue":"8","key":"6333_CR8","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","volume":"91","author":"AC Antoniou","year":"2004","unstructured":"Antoniou AC, Pharoah PP, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580\u20131590. https:\/\/doi.org\/10.1038\/sj.bjc.6602175","journal-title":"Br J Cancer"},{"issue":"11","key":"6333_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/jmg.40.11.807","volume":"40","author":"E Amir","year":"2003","unstructured":"Amir E, Evans DG, Shenton A et al (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807\u2013814","journal-title":"J Med Genet"},{"issue":"5182","key":"6333_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66\u201371","journal-title":"Science"},{"issue":"6559","key":"6333_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789\u2013792","journal-title":"Nature"},{"issue":"23","key":"6333_CR12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372(23):2243\u20132257","journal-title":"N Engl J Med"},{"key":"6333_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01907","author":"X Yang","year":"2019","unstructured":"Yang X, Leslie G, Doroszuk A et al (2019) Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.01907","journal-title":"J Clin Oncol"},{"issue":"2","key":"6333_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/ijc.26394","volume":"131","author":"A Maurice","year":"2012","unstructured":"Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A (2012) Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit. Int J Cancer 131(2):417\u2013425","journal-title":"Int J Cancer"},{"issue":"12","key":"6333_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(10)70263-1","volume":"11","author":"FH01 collaborative teams","year":"2010","unstructured":"FH01 collaborative teams (2010) Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol 11(12):1127\u20131134","journal-title":"Lancet Oncol"},{"key":"6333_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.eclinm.2019.01.005","volume":"7","author":"DG Evans","year":"2019","unstructured":"Evans DG, Thomas S, Caunt J et al (2019) Final results of the prospective FH02 mammographic surveillance study of women aged 35\u201339 at increased familial risk of breast cancer. EClinicalMedicine 7:39\u201346","journal-title":"EClinicalMedicine"},{"issue":"9473","key":"6333_CR17","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","volume":"365","author":"MO Leach","year":"2005","unstructured":"Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769\u20131778","journal-title":"Lancet"},{"issue":"33","key":"6333_CR18","doi-asserted-by":"publisher","first-page":"8469","DOI":"10.1200\/JCO.2004.00.4960","volume":"23","author":"CK Kuhl","year":"2005","unstructured":"Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469\u20138476","journal-title":"J Clin Oncol"},{"issue":"5","key":"6333_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa031759","volume":"351","author":"M Kriege","year":"2004","unstructured":"Kriege M, Brekelmans CT, Boetes C, Magnetic Resonance Imaging Screening Study Group et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427\u2013437","journal-title":"N Engl J Med"},{"issue":"11","key":"6333_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","volume":"292","author":"E Warner","year":"2004","unstructured":"Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317\u20131325","journal-title":"JAMA"},{"issue":"1","key":"6333_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, IBIS-I Investigators (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)71171-4","journal-title":"Lancet Oncol"},{"issue":"10218","key":"6333_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A, IBIS-II investigators (2020) Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 395(10218):117\u2013122. https:\/\/doi.org\/10.1016\/S0140-6736(19)32955-1","journal-title":"Lancet"},{"key":"6333_CR23","doi-asserted-by":"publisher","DOI":"10.3310\/pgfar04110","volume-title":"Improvement in risk prediction, early detection and prevention of breast cancer in the NHS breast screening programme and family history clinics: a dual cohort study","author":"DG Evans","year":"2016","unstructured":"Evans DG, Astley S, Stavrinos P et al (2016) Improvement in risk prediction, early detection and prevention of breast cancer in the NHS breast screening programme and family history clinics: a dual cohort study. NIHR Journals Library, Southampton"},{"issue":"2","key":"6333_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10689-013-9694-z","volume":"13","author":"DG Evans","year":"2014","unstructured":"Evans DG, Ingham S, Dawe S et al (2014) Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Fam Cancer 13(2):189\u2013196","journal-title":"Fam Cancer"},{"issue":"5","key":"6333_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L, Carvalho S, Allen J et al (2021) Breast cancer risk genes: association analysis of rare coding variants in 34 genes in 60,466 cases and 53,461 controls. N Engl J Med 384(5):428\u2013439","journal-title":"N Engl J Med"},{"issue":"9","key":"6333_CR26","first-page":"531","volume":"21","author":"SJ Howell","year":"2017","unstructured":"Howell SJ, Hockenhull K, Salih Z, Evans DG (2017) Increased risk of breast cancer in neurofibromatosis type 1: current insights. Breast Cancer (Dove Med Press) 21(9):531\u2013553","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"6333_CR27","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"SR Lakhani","year":"2002","unstructured":"Lakhani SR, Van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310\u20132318","journal-title":"J Clin Oncol"},{"issue":"23","key":"6333_CR28","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.7112","journal-title":"JAMA"},{"issue":"9","key":"6333_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/jmedgenet-2014-102336","volume":"51","author":"DG Evans","year":"2014","unstructured":"Evans DG, Harkness E, Lalloo F, Howell A (2014) Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. J Med Genet 51(9):573\u2013580","journal-title":"J Med Genet"},{"issue":"11","key":"6333_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812\u2013822","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6333_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10549-014-2931-9","volume":"145","author":"DG Evans","year":"2014","unstructured":"Evans DG, Kesavan N, Lim Y, Gadde S et al (2014) MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 145(3):663\u2013672","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"6333_CR32","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/cancers12113479","volume":"12","author":"E Warner","year":"2020","unstructured":"Warner E, Zhu S, Plewes DB et al (2020) Breast cancer mortality among women with a BRCA1 or BRCA2 mutation in a magnetic resonance imaging plus mammography screening program. Cancers (Basel) 12(11):3479","journal-title":"Cancers (Basel)"},{"key":"6333_CR33","unstructured":"https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/survival#heading-Zero. Accessed 20 July 2020"},{"issue":"2","key":"6333_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson ER, Maishman TC, Tapper WJ et al (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19(2):169\u2013180","journal-title":"Lancet Oncol"},{"issue":"6","key":"6333_CR35","doi-asserted-by":"publisher","first-page":"e207227","DOI":"10.1001\/jamanetworkopen.2020.7227","volume":"3","author":"VL Irvin","year":"2020","unstructured":"Irvin VL, Zhang Z, Simon MS et al (2020) Comparison of mortality among participants of women\u2019s health initiative trials with screening-detected breast cancers vs interval breast cancers. JAMA Netw Open 3(6):e207227","journal-title":"JAMA Netw Open"},{"issue":"2","key":"6333_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/jmedgenet-2016-104125","volume":"54","author":"DG Evans","year":"2017","unstructured":"Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A, Newman WG, Cuzick J, FH-risk study Group (2017) The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. J Med Genet 54(2):111\u2013113","journal-title":"J Med Genet"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06333-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06333-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06333-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T14:46:20Z","timestamp":1633963580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06333-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["6333"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06333-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-236542\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"12 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DGE has received consultancy fees from Astrazeneca and Springworks. There are no other conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}